Sector News

Teva CFO: We’re looking to grow sales, not slash and burn costs

September 10, 2014
Life sciences
You can rest easy, Teva workers–your jobs are safe, according to CFO Eyal Desheh. On Monday, he told listeners at the Morgan Stanley Global Healthcare Conference in New York that the Israeli drugmaker has no new plans for major cutbacks.
 
“I want to be very careful because this is a major managerial challenge: Reduce your costs, become more efficient, and at the same time grow the business and enter new areas,” he said, as quoted by the Philadelphia Inquirer. “That’s a little bit contradictive. I think we can do both, but another cost-cutting round will be counterproductive to growth.”
 
The statement follows an earlier round of job-cutting, announced last October, that touched off protests throughout Teva’s home country and led to the exit of then-CEO Jeremy Levin. After announcing plans to lay off up to 5,000 people, or about 10% of its workforce, in a bid to slash $2 billion from its annual costs by 2017, Teva saw Levin depart amid a board squabble that spurred its own backlash from shareholders.
 
So without jobs on the block, how does the generics giant plan to hit that cost-savings target? The way Desheh sees it, the company can still lean on its plans to squeeze out $1 billion by changing up procurement. Previously, every small unit within the company did its own purchasing, a practice he called “inefficient.”
 
“Right now, we spend about $10 billion a year buying from others–all kinds of stuff,” he said. “Materials, machines, finished products–not a lot but some–services, rent, you name it. Everything we spend, other than royalties and cost of labor, we consolidated under one head of global procurement.”
 
Cost pressures, like the rest of Teva’s woes–the patent battle over lead product Copaxone, rebel investor pressure for a board revamp–won’t disappear overnight. And even when they do, Desheh cautioned, don’t look for a decrease in total spending. By 2017 or 2018, he hopes to see a stronger company growing, he said.
 
By Carly Helfand
 

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.